PD-L1 in Cytological Samples: A Review and a Practical Approach

Area of Science:

• Oncology
• Pathology
• Biomarker Analysis

Background:

• Non-small cell lung cancer (NSCLC) management increasingly relies on predictive biomarkers.
• Immunohistochemistry (IHC) is a cost-effective method for biomarker testing, particularly for programmed death ligand-1 (PD-L1) in immunotherapy.
• Formalin-fixed paraffin-embedded (FFPE) specimens are standard for PD-L1 assays, but research is expanding to cytological samples.

Purpose of the Study:

• To review the role of cytopathology in analyzing PD-L1 expression for immunotherapy.
• To discuss the feasibility and challenges of using cytological samples for PD-L1 testing.
• To outline future directions for cytopathology in the context of cancer immunotherapy.

Main Methods:

• Literature review summarizing current knowledge on PD-L1 testing in cytopathology.
• Analysis of existing research on immunocytochemistry (ICC) for PD-L1 in NSCLC.
• Identification of key issues in applying PD-L1 assays to cytological specimens.

Main Results:

• IHC is the primary method for PD-L1 assessment in NSCLC, guiding immunotherapy decisions.
• Promising results exist for PD-L1 testing on cytological samples, but standardization is needed.
• Challenges include sample type, pre-analytical variables, cyto-histological correlation, and inter-observer agreement.

Conclusions:

• Cytopathology shows potential for PD-L1 analysis in NSCLC patients undergoing immunotherapy.
• Addressing pre-analytical factors and ensuring reliable cyto-histological correlation are critical for clinical implementation.
• Further research is needed to optimize ICC methods and establish inter-observer agreement for cytological PD-L1 testing.